Two pieces this week captured the state of gene‑based medicine: a review noting 2025 as a breakout year for in vivo gene therapies and an industry dispatch on the proliferation of gene‑editing platforms. The review highlights advances in delivery and preclinical success that pushed multiple in vivo programs forward; the accompanying analysis documents an expanding toolkit of editors and delivery strategies as companies chase a broadly adoptable ‘final’ editing technology.